Angela Harmantas

6 days ago | proactiveinvestors.com | Angela Harmantas

Mining This record is published on behalf of Lancaster Resources Inc, a paid client of ProactiveAbout this content Disclaimer No investment advice About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks.

1 week ago | proactiveinvestors.com | Angela Harmantas

EnergyOil & Gas This record is published on behalf of Alvopetro Energy Ltd, a paid client of ProactiveAbout this content Disclaimer No investment advice About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks.

1 week ago | proactiveinvestors.com | Angela Harmantas

The shelves at major U.S. retailers may look full for now, but a dramatic slowdown in trade between the U.S. and China is quietly building into what could become a full-blown supply shock. In this guest article, Frank Holmes, CEO of U.S. Global Investors (NASDAQ:GROW), breaks down how President Trump’s sweeping new tariffs—some as high as 145%—are already reshaping shipping patterns, threatening retail inventory, and prompting layoffs in freight and logistics.

1 week ago | proactiveinvestors.com | Angela Harmantas

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Friday that a patient with moderate Alzheimer’s disease showed a marked reduction in brain inflammation after three months of treatment with its lead drug candidate, intranasal foralumab, under an expanded access program. A PET scan revealed a significant decrease in microglial activation—an indicator of neuroinflammation linked to Alzheimer’s progression—according to data presented by Dr Howard Weiner at the 2025 AD/PD Conference in Vienna.

1 week ago | proactiveinvestors.com | Angela Harmantas

Lisata Therapeutics Inc (NASDAQ:LSTA) said on Thursday it expects a data-rich year ahead as it advances multiple trials of its lead asset, certepetide, a novel peptide-based therapy being tested in a range of solid tumors.